At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 6 enrolled
Drug / intervention
Terlipressin acetate continuous infusiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Low-dose Terlipressin Delivered by Continuous Intravenous Infusion in Patients With Cirrhosis and Ascites Refractory to, or Intolerant of, Diuretic Therapy, Requiring Large Volume Paracentesis
In Brief
A Phase 2 clinical trial evaluating Terlipressin acetate continuous infusion for Cirrhosis and Ascites Hepatic. Completed, enrolled 6 participants across 1 site.
Detailed Summary
Low-dose continuous infusion of terlipressin will be administered to six cirrhotic patients with refractory ascites.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCirrhosis, Ascites Hepatic
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartJul 2017
Primary CompletionApr 2019
Study CompletionApr 2019
TodayJul 2026
First PostedApr 11, 2017
Enrollment StartJul 15, 2017
Primary CompletionApr 1, 2019
Study CompletionApr 25, 2019
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 9.2 years ago
Interventions
Terlipressin acetate continuous infusiondrug
Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days